Community clinic participation is redefining what effective clinical trial recruitment looks like in the United States. Sponsors who once defaulted to academic medical centers and standalone research facilities are now recognizing a fundamental truth: the patients who need access to trials are not sitting in university hospitals. They are in community clinics, specialty practices, and regional health systems across the country, and reaching them requires a different model entirely.
This guide breaks down how community clinic participation works, why it outperforms traditional recruitment infrastructure, and what sponsors and CRO clinical operations leaders should evaluate before selecting a site partner for their next study.
Why Community Clinic Participation Is Replacing Traditional Recruitment Models
For decades, clinical trial recruitment depended on patients finding their way to a dedicated research site, usually through advertising, a patient registry, or a referral from their primary physician. Each of those pathways introduces friction that compounds across a study and drives enrollment delays.
Community clinic participation eliminates most of that friction by bringing the trial to the patient rather than the other way around. When a study is embedded inside the clinic where a patient already receives care, the recruiting physician is someone the patient already trusts. Eligibility is identified through an existing care relationship, not through a screening ad. The consent conversation happens in a familiar room, not a research facility the patient has never entered.
The structural effect is measurable. Community clinic participation consistently produces higher consent rates, lower screen failure rates, and stronger participant retention compared to traditional site models. For sponsors managing tight development timelines, these are not incremental gains. They are competitive advantages built into the recruitment infrastructure from day one.
The Patient Access Problem That Community Clinic Participation Solves
Patient access to trials has become a regulatory, scientific, and operational priority simultaneously. Regulators are requiring more representative trial populations. Payers are scrutinizing whether trial data reflects the real-world patients a therapy will serve. And sponsors are discovering that enrollment built on narrow, self-selecting populations produces data that may not generalize at launch.
Community clinic participation addresses the access problem at its root. Patients in underserved communities, including Black, Hispanic, rural, and elderly populations, are far more likely to receive care in a community setting than to seek out a research center independently. When trials are embedded where those patients already are, diverse enrollment becomes a function of site selection rather than a separate outreach campaign.
The FDA Diversity Action Plan now requires sponsors of certain trials to submit formal plans for enrolling representative populations. Community clinic participation is the most operationally reliable way to meet that requirement consistently across a multi-site study.
5 Factors That Define High-Performing Community Clinic Participation Networks
Community clinic participation is not a uniform capability. Networks vary significantly in how deeply they are embedded in care settings, how consistently they perform across therapeutic areas, and how rigorously they manage quality. Sponsors and CRO leaders should evaluate partners across these five dimensions.
1. Depth of Embedding in Care Settings
The most important distinction in community clinic participation is whether the network is genuinely embedded in clinical care or simply contracted to recruit from community locations. Genuine embedding means investigators are practicing physicians whose research activity is integrated into their clinical workflow. Patient identification happens through the EHR, not through external campaigns. The research visit happens in the same facility as the care visit.
Networks that are loosely affiliated with community sites produce inconsistent community clinic participation outcomes. Look for infrastructure that is built into the clinic, not bolted onto it.
2. Therapeutic Area Track Record
Community clinic participation delivers its strongest results when the network has deep experience in the indication being studied. Sites with existing patient populations in your therapeutic area activate faster, screen more efficiently, and retain more participants. Ask for enrollment performance data from comparable past studies registered at ClinicalTrials.gov, and verify that the data reflects community clinic participation specifically, not academic or hybrid site performance.
3. Diversity Enrollment by Design
Evaluate whether diversity is built into the community clinic participation model or pursued as a remediation effort after enrollment falls short. Strong networks have multilingual outreach capabilities, sites located in communities with underrepresented populations, and historical diversity data they can share by study. If a partner cannot produce that data, diversity enrollment is not a built-in capability.
4. Regulatory and Quality Infrastructure
Community clinic participation does not mean reduced regulatory rigor. The best embedded networks operate with centralized quality oversight, continuous data monitoring, eSource and eConsent capabilities, and documentation standards that support remote monitoring and sponsor access. Evaluate this infrastructure as carefully as you evaluate site footprint.
5. Activation Speed
One of the clearest operational advantages of community clinic participation is faster site activation. Networks with established investigators, existing IRB relationships, and standardized startup processes can move from award to first patient enrolled significantly faster than greenfield site identification. Request real activation timelines, not projections, and ask for data from studies with comparable protocol complexity.
How Care Setting Trials Differ From the Academic Research Model
Understanding the structural difference between care setting trials and academic research models helps sponsors make better infrastructure decisions earlier in the planning process.
Academic medical centers bring significant advantages: dedicated research staff, established IRB relationships, and experience with complex early-phase protocols. Their limitation is population access. Academic centers draw from a self-selecting patient base that tends to be more educated, more geographically proximate to the institution, and less representative of the disease burden across the general population.
Care setting trials embedded through community clinic participation draw from the population the clinic actually serves. The investigator is a practicing physician. The patient is already in care. Research participation is offered as an extension of that care relationship, not as a separate activity the patient must seek out independently.
For Phase II and Phase III trials in therapeutic areas with high community prevalence, including gastroenterology, endocrinology, rheumatology, cardiovascular disease, and oncology, care setting trials consistently outperform the academic model on enrollment speed, population diversity, and participant retention.
What to Ask a Community Clinic Participation Partner Before Committing
Before selecting a partner for community clinic participation in your next U.S. trial, clinical operations teams should ask the following:
What percentage of your investigators are actively practicing physicians in community care settings? What is your median time from site activation to first patient enrolled, based on comparable past studies? What share of enrolled patients are identified through internal EHR prescreening versus external advertising? What does your diversity enrollment look like across your last ten studies? How do you maintain quality oversight and data integrity across a distributed site network? Which therapeutic areas do you have the deepest community clinic participation track record in?
The answers will reveal whether a partner is genuinely built for community clinic participation or applying that language to a conventional site network.
Building a Community Clinic Participation Strategy for 2026
Sponsors planning studies in 2026 and beyond should approach community clinic participation as a strategic infrastructure decision, not a recruitment tactic.
At the site selection level, prioritize networks with demonstrated embedding over networks with large site counts and shallow community relationships. A smaller network of genuinely integrated sites will outperform a larger network of loosely affiliated ones in every enrollment metric that matters.
At the protocol level, engage community clinic participation partners early in study design. Visit windows, assessment schedules, and logistical requirements that are manageable in an academic center may create real barriers in a community clinic. Early input from embedded site networks reduces protocol-driven dropout before the study opens.
At the operational level, confirm that your community clinic participation partner has the technology infrastructure, quality systems, and regulatory capabilities to support your monitoring and data requirements. Community proximity and regulatory rigor are not in conflict. The best embedded networks deliver both.
Ready to evaluate community clinic participation for your next trial?
FOMAT Medical Research is an Embedded Research Organization with more than 40 investigator sites, 80 investigators, and presence across 6 states. Learn more about FOMAT’s Phase II and III clinical trial capabilities or contact the business development team directly at [email protected] or (805) 483-1185.